Over $500bn in prescription drug sales face generic competition by 2032. Which companies are most exposed, and what are they doing about it? Find out in the Evaluate World Preview 2026: vist.ly/5pfti

Lilly is forecast to hit $137bn in annual drug sales by 2032. Download the Evaluate World Preview 2026 to see who's pulling ahead and why obesity and autoimmune are doing most of the heavy lifting. Download it here: vist.ly/5p6dc

The FDA approved 22 novel drugs in Q3 2026, the busiest quarter of the year so far and well ahead of Q2. Evaluate Pharma forecasts put the cohort at $31B in 2032 sales. Evaluate’s Paul Verdin looks at the new drugs ready to hit the market in Nature: vist.ly/5p68r

Evaluate helps you navigate market trends—forecasts, competitive positioning, and more—to drive portfolio growth. Norstella connects R&D, market access, and commercialization, trusted by Top 100 pharma and industry experts. Follow @NorstellaCo to see how we complete the puzzle.

Every forecast change has a reason. Broker Assumptions in Evaluate Pharma links forecast movements to the underlying assumptions, while Ask Ella helps you uncover the why in seconds. Explain revisions in minutes, not hours. Log in: vist.ly/5nzff

Evaluate Spotlight Ep.04: Cardiovascular is live! CV sales are forecast to grow 11% annually through 2032, driven by new entrants, launches, and emerging modalities. Hear from Mary Anderson and Jessica Merrill on the trends reshaping the market. Watch: vist.ly/5nzaa.

Evaluate Spotlight Ep.03: Immunology is live! Explore the trends, deals, and innovations shaping one of pharma’s fastest-growing therapy areas. ▶️ Watch now: vist.ly/5npbz 🔒 Up next: Cardiovascular | 19 Oct

The next opportunity may already be taking shape. Value can move before the market fully catches up. Track the companies, assets and catalysts shaping biopharma to see where opportunity may be emerging next. 🎯 Stay ahead of market shifts: vist.ly/5nmxc

Thousands of biopharma leaders start their month with Evaluate Discovery. Join them for sharp analysis, must-read insights, and the trends that matter, delivered monthly. Ready to be in the know? ✨ vist.ly/5nbg2

Broker Assumptions is now live in Evaluate Pharma. It links forecast movements to the broker assumptions driving them, with Ask Ella giving you conversational access in seconds. Log in now and just ask > vist.ly/5n73i

Last chance to register. Join Evaluate's CI leaders today at 3 PM BST / 10 AM ET for practical guidance on applying productivity benchmarks to competitor analysis. vist.ly/5n5us

Tomorrow, Evaluate's CI leaders will unpack the 2026 Pipeline-to-Patient Productivity Index and show how competitive intelligence teams can translate the macro findings to inform indication-level competitor analyses, leveraging real examples throughout. vist.ly/5mzvx

The people behind the platform make the difference. Atlas CI is built by experts with deep biopharma experience, helping turn complexity into confidence. Learn more: vist.ly/5mzdf

"I consider myself an expert; I’ve been doing this for decades and can now do it in 10 minutes." – a Business Development Strategist at a global med-tech company on Atlas CI from @NorstellaCo, an AI agent for competitive intelligence. Learn more: vist.ly/5myhr

Drug approvals are taking longer, with median Phase I-to-approval timelines reaching 9.3 years. Join Evaluate's CI leaders on Oct. 13 to learn how to apply this insight to smarter competitor timeline forecasts. vist.ly/5mt3c

The 2026 Pipeline-to-Patient Productivity Index reveals a key shift: the industry is failing earlier. Join Evaluate's CI experts on Oct. 13 to learn what this means for competitor pipeline analysis. vist.ly/5mphz

What happens to the thesis when one assumption changes? Pressure-test the forecasts, catalysts, competition, and market signals underpinning a company or asset. Stress-test your assumptions. vist.ly/5mni3

From industry benchmarks to competitor-specific signals. Join Kelly Chamberlain & Adam Schaffner on Oct. 13 to see how CI teams can spot and act on critical pipeline trends. vist.ly/5mif9

What’s the current oncology landscape? Ep. 02 of Evaluate Spotlight covers key insights: M&A is now targeted, ADCs and bispecifics have surged, half of top companies lack growth potential, and funding cuts may impact the early-stage pipeline. ▶️ Watch: vist.ly/5mhqk

Weeks to months of competitive pipeline research. A skeptic did it in 10 minutes. A Business Development Strategist with decades of experience got a very similar output from @NorstellaCo Atlas CI, an AI agent for competitive intelligence. Learn more: vist.ly/5mc9x